SCHEMBL3801667

SCHEMBL3801667

COc1cc(C(N)=O)c(F)cc1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.47
PARP10 Q53GL7 2/20 0.45
PARP14 Q460N5 1/20 0.45
ALDH1A1 P00352 3/20 0.44
GAA P10253 3/20 0.44
GLA P06280 1/20 0.44
HPGD P15428 1/20 0.44
HTT P42858 4/20 0.43
LMNA P02545 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
PARP15 Q460N3 1/20 0.42
POLB P06746 2/20 0.41
DGAT1 O75907 1/20 0.41
PKM P14618 1/20 0.40
MAPK1 P28482 1/20 0.39
RAB9A P51151 1/20 0.39
S100B P04271 1/20 0.39
CYP3A4 P08684 1/20 0.38
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28143231 0.87 PARP10 (0.48) KDM4EPARP10PARP14ALDH1A1GAA
SCHEMBL2310679 0.86 KDM4E (0.51) KDM4EPARP10PARP14ALDH1A1GAA
SCHEMBL1163576 0.86 ALDH1A1 (0.50) KDM4EALDH1A1GAAHPGDHTT
SCHEMBL29811842 0.86 ALDH1A1 (0.50) KDM4EALDH1A1GAAHPGDHTT
SCHEMBL221470 0.84 KDM4E (0.64) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL6814511 0.83 KDM4E (0.56) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL3339070 0.82 PARP10 (0.45) KDM4EPARP10PARP14ALDH1A1GAA
SCHEMBL13575580 0.81 KDM4E (0.47) KDM4EALDH1A1GAAHPGDHTT
SCHEMBL15652061 0.81 KDM4E (0.44) KDM4EALDH1A1GAAHTTLMNA
SCHEMBL23155695 0.81 PARP10 (0.44) KDM4EPARP10PARP14ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3919488-B1 IMMUNOMODULATOR HITGEN INC (CN) 2025-08-27 EP disclosed
CN-113563313-B Immunomodulator 成都先导药物开发股份有限公司 2022-11-04 CN disclosed
US-20220119379-A1 IMMUNOMODULATOR HITGEN INC. (CN) 2022-04-21 US disclosed
US-20220119379-A1 IMMUNOMODULATOR HITGEN INC. (CN) 2022-04-21 US disclosed
EP-3919488-A1 IMMUNOMODULATOR Hitgen Inc. (CN) 2021-12-08 EP disclosed
EP-3919488-A1 IMMUNOMODULATOR Hitgen Inc. (CN) 2021-12-08 EP disclosed
CN-113563313-A Immunomodulator 成都先导药物开发股份有限公司 2021-10-29 CN disclosed
CN-111499617-B Immunomodulator 成都先导药物开发股份有限公司 2021-08-06 CN disclosed
WO-2021061643-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2021-04-01 WO disclosed
CN-111499617-A Immunomodulator 成都先导药物开发股份有限公司 2020-08-07 CN disclosed
WO-2020156363-A1 IMMUNOMODULATOR 成都先导药物开发股份有限公司 2020-08-06 WO disclosed
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-06-10 US disclosed
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-06-10 US disclosed
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-06-10 US disclosed
US-20100075973-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-25 US disclosed
WO-2010025073-A1 DIHYDROIMIDAZO [ 1, 5-F] PTERIDINES AS POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-04 WO disclosed
WO-2009153197-A1 HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-12-23 WO disclosed
WO-2008040951-A1 COMPOUNDS ASTRAZENECA AB (SE) 2008-04-10 WO disclosed
EP-1899353-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DeveloGen Aktiengesellschaft (DE) 2008-03-19 EP disclosed
WO-2006136402-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075973-A1 POLO-LIKE KINASE INHIBITORS PLK2, PLK4, PLK1 KDM4E 1785/4885PARP10 549/4885PARP14 689/4885
US-20220119379-A1 IMMUNOMODULATOR STING1, TLR9, CGAS KDM4E 4205/4885PARP10 498/4885PARP14 949/4885
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DTYMK, CMPK1, PDXK KDM4E 2624/4885PARP10 896/4885PARP14 1458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.